{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T09:32:05Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 21.3, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a094f4-9474-7182-a651-32a4ff386c4c\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: estradiol cypionate\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 043: ", "usd": 0.0, "recall": true }, "codex": { "seconds": 74.2, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a094f4-946c-71d1-972f-650770e9c6b1\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: estradiol cypionate\nRegistry id: vr.tr.estradiol-cypionate\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this " } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:57:40+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "standards_and_regulation", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:31+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q5401760", "registryId": "vr.tr.estradiol-cypionate", "name": "estradiol cypionate", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q5401760/", "model": { "registry_id": "vr.tr.estradiol-cypionate", "name": "estradiol cypionate", "purpose": "Enable an AI agent to identify estradiol cypionate, assess the identity and condition of a particular material lot, and determine whether evidence supports its intended handling or use.", "definition": "Estradiol cypionate is the 17β-cyclopentylpropionate ester of estradiol, a synthetic estrogen prodrug that is hydrolyzed to estradiol and used in long-acting injectable preparations.", "scope_statement": "This model owns estradiol cypionate as a defined chemical substance, including its estradiol ester identity, material grades, lot quality, physical condition, stability and substance-level restrictions, while linking separately to formulated medicines and clinical decisions.", "in_scope": [ "Chemical identity, stereochemistry and the cypionate ester relationship to estradiol", "Substance identifiers and their correspondence to the same molecular identity", "Lot composition, assay, impurities and documented material grade", "Physical form, measured properties and the conditions under which measurements apply", "Storage history, degradation evidence and fitness for an explicitly stated material use", "Substance-specific handling hazards and jurisdiction-dependent regulatory identity" ], "out_of_scope": [ "Finished injectable formulations, their excipients, concentration, packaging and administration instructions", "Patient-specific prescribing, dosing, treatment monitoring and clinical eligibility", "Estradiol and other estradiol esters as independently managed substances", "Manufacturing equipment and complete synthesis-process models", "Product marketing authorisations and supply-chain organisations as independent entities" ], "distinguishing_features": [ "The assigned molecular structure must identify the cypionate ester of estradiol, rather than unesterified estradiol.", "The ester substituent must distinguish cypionate from valerate, benzoate and other estradiol esters; a shared estrogen-related name is insufficient.", "The structural assignment must resolve the ester attachment site and estradiol stereochemistry rather than relying only on a molecular formula.", "A material described as estradiol cypionate in an oil vehicle is a formulation containing the substance, not the neat substance itself.", "Assay statements must distinguish mass of estradiol cypionate from any quantity expressed as an estradiol equivalent." ], "characteristics": [ { "name": "Molecular identity", "kind": "category", "unit_or_values": "Verified structure with ester attachment site and stereochemistry; associated canonical identifiers", "why_it_matters": "Separates estradiol cypionate from estradiol, other esters and incorrectly labelled materials." }, { "name": "Identifier correspondence", "kind": "relation", "unit_or_values": "Source-qualified links to CAS, PubChem and applicable regulatory records", "why_it_matters": "Prevents records for a formulation or another estradiol derivative from being merged into this substance." }, { "name": "Material grade", "kind": "category", "unit_or_values": "Supplier-declared grade, applicable specification and evidence of conformity", "why_it_matters": "A chemical name alone does not establish suitability for pharmaceutical manufacture or another intended use." }, { "name": "Estradiol cypionate assay", "kind": "measurement", "unit_or_values": "% mass fraction with method, uncertainty where available, and as-is or corrected basis", "why_it_matters": "Establishes how much of a lot is the named ester and makes assay comparisons interpretable." }, { "name": "Related substances and residuals", "kind": "measurement", "unit_or_values": "% or mg/kg by analyte, with method and detection or quantification limits", "why_it_matters": "Distinguishes intact ester from free estradiol, other related substances and process residuals." }, { "name": "Physical form and thermal behaviour", "kind": "state", "unit_or_values": "Observed solid form and appearance; thermal transitions in °C with method and sample conditions", "why_it_matters": "Supports material recognition and investigation of unexpected lot behaviour." }, { "name": "Solubility under specified conditions", "kind": "measurement", "unit_or_values": "mg/mL or mol/L with solvent, temperature, method and equilibration conditions", "why_it_matters": "Supports analytical preparation and material processing without treating an oil formulation as a property of the neat substance." }, { "name": "Storage and quality disposition", "kind": "state", "unit_or_values": "Storage conditions and excursions; released, quarantined, rejected or awaiting assessment", "why_it_matters": "Connects the lot's history and analytical evidence to permitted material operations." }, { "name": "Hazard and regulatory status", "kind": "category", "unit_or_values": "Source-, date- and jurisdiction-qualified classifications, restrictions and unresolved applicability", "why_it_matters": "Supports handling and supply decisions without transferring finished-medicine rules automatically to the raw substance." } ], "affordances": [ "Resolve a label or supplier record to the verified estradiol cypionate identity.", "Compare a lot's assay and impurity evidence with the specification required for its intended use.", "Select documented analytical preparation conditions using solvent-specific property evidence.", "Flag storage excursions or analytical changes for degradation assessment and quarantine where warranted.", "Determine which handling, transfer or disposal requirements apply to the documented material and jurisdiction.", "Link the substance to a formulation while preserving the distinction between ester content, estradiol equivalents and finished-product concentration." ], "agent_conduct": { "may": [ "Identify estradiol cypionate by name, identifiers and documented properties, citing sources.", "Report approved uses and warnings from official product information.", "Check a material lot's certificate of analysis against its specification." ], "must_not": [ "Recommend a dose or regimen for a particular person.", "Disclose or infer a person's hormone therapy, gender identity or health status without consent.", "Supply it outside lawful pharmaceutical or veterinary channels.", "Spread misinformation or stigma about people who use hormone therapy." ], "requires_human": [ "Any decision to start, stop or change hormone therapy.", "Releasing or destroying a material lot." ] }, "ethics": { "considerations": [ "Hormone therapy touches on private matters of health and identity that deserve dignity.", "Unsupervised use carries clot and cancer risks." ], "affected_parties": [ "People receiving hormone therapy", "Prescribers and pharmacists", "Manufacturing staff" ] }, "owners": { "steward": "The marketing authorization holder for each medicine; the national medicines regulator oversees it.", "master_systems": [ "National medicines registers" ] }, "visual_identification": [ "Identity rests on the label, batch record and certificate of analysis, not appearance.", "Usually supplied as an oily solution for injection, named on the vial." ], "failure_modes_and_hazards": [ "Raised risk of blood clots and hormone-sensitive cancers.", "Injection-site problems with unsafe practice.", "Counterfeit or unregulated products." ], "standards_and_regulation": [ "ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, International Council for Harmonisation." ], "what_it_is_for": [ "Estradiol cypionate is encountered as an active pharmaceutical ingredient in long-acting injectable estrogen preparations.", "It is also used in pharmaceutical analysis and research where the ester, formulation and material identity must be distinguished from estradiol itself." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q5401760: estradiol cypionate", "url": "https://www.wikidata.org/wiki/Q5401760", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Estradiol cypionate", "url": "https://en.wikipedia.org/wiki/Estradiol_cypionate", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "estradiol-cypionate-identity", "name": "Estradiol cypionate identity", "description": "Defines the structural and documentary evidence required to recognise the named estradiol ester.", "rationale": "Confusion between estradiol esters can survive name matching and propagate into assay, formulation and regulatory records.", "layers": [ { "id": "ester-structure", "name": "Ester structure", "description": "Resolves the estradiol parent, cypionate substituent, attachment site and stereochemical identity.", "findings": [ { "id": "structure-based-recognition", "name": "Structure-based recognition", "description": "The model requires a referenced structural assignment that differentiates this ester from estradiol and neighbouring estradiol derivatives.", "questions": [ { "text": "Which authoritative structure establishes the cypionate substituent, its attachment site and the stereochemistry of estradiol cypionate?", "kind": "definition", "id": "structure-based-recognition-q01" }, { "text": "What identity evidence distinguishes the received material from free estradiol and other estradiol esters?", "kind": "measurement", "id": "structure-based-recognition-q02" } ] } ] }, { "id": "identifiers-and-boundaries", "name": "Identifiers and boundaries", "description": "Connects chemical records while separating the substance from products containing it.", "findings": [ { "id": "identifier-and-product-resolution", "name": "Identifier and product resolution", "description": "Identifiers and synonyms need explicit source correspondence; product names remain links to formulations.", "questions": [ { "text": "Which CAS, PubChem and applicable EC records have been checked against the same estradiol cypionate structure?", "kind": "provenance", "id": "identifier-and-product-resolution-q01" }, { "text": "Does a supplied name identify the chemical substance, a material grade or an estradiol cypionate formulation?", "kind": "boundary", "id": "identifier-and-product-resolution-q02" } ] } ] } ] }, { "id": "ester-content-and-lot-quality", "name": "Ester content and lot quality", "description": "Captures evidence that a particular lot contains the intended ester at a quality appropriate to its proposed use.", "rationale": "Verified identity alone does not establish assay, impurity limits or pharmaceutical suitability.", "layers": [ { "id": "assay-and-reporting-basis", "name": "Assay and reporting basis", "description": "Makes measurements of ester content comparable and interpretable.", "findings": [ { "id": "ester-assay-basis", "name": "Ester assay basis", "description": "Assay evidence must identify the measured species, reference standard and correction basis.", "questions": [ { "text": "What measured assay does the lot have, by which method and against which qualified estradiol cypionate reference standard?", "kind": "measurement", "id": "ester-assay-basis-q01" }, { "text": "Is the reported quantity intact estradiol cypionate or an estradiol equivalent, and is its basis as-is, dried or otherwise corrected?", "kind": "definition", "id": "ester-assay-basis-q02" } ] } ] }, { "id": "impurities-and-grade", "name": "Impurities and grade", "description": "Relates related-substance and residual measurements to a documented material specification.", "findings": [ { "id": "lot-quality-evidence", "name": "Lot quality evidence", "description": "Grade claims require lot-specific support, including discrimination of the ester from free estradiol and other relevant impurities.", "questions": [ { "text": "Which related substances, including free estradiol, and which process residuals are measured or controlled for this lot?", "kind": "measurement", "id": "lot-quality-evidence-q01" }, { "text": "Which specification and certificate support the declared grade, and what intended material use does that specification cover?", "kind": "provenance", "id": "lot-quality-evidence-q02" }, { "text": "Do the results support release for the stated use, or is further testing or quarantine required?", "kind": "action", "id": "lot-quality-evidence-q03" } ] } ] } ] }, { "id": "physical-behaviour-and-ester-stability", "name": "Physical behaviour and ester stability", "description": "Describes the material's physical condition, solvent behaviour and evidence of change during storage or preparation.", "rationale": "Measurements from the neat ester and from formulated solutions are not interchangeable, and deterioration requires evidence specific to the material conditions.", "layers": [ { "id": "solid-and-solvent-behaviour", "name": "Solid and solvent behaviour", "description": "Records physical-property observations under explicit experimental conditions.", "findings": [ { "id": "conditioned-property-evidence", "name": "Conditioned property evidence", "description": "Physical constants and solubility records require methods and conditions sufficient to judge whether they apply to the lot.", "questions": [ { "text": "What physical form and melting or other thermal behaviour are supported by measurements for estradiol cypionate, and under what conditions?", "kind": "measurement", "id": "conditioned-property-evidence-q01" }, { "text": "What solubility is demonstrated in each relevant analytical or processing solvent at the specified temperature?", "kind": "measurement", "id": "conditioned-property-evidence-q02" }, { "text": "Does each property describe the neat ester, a characterised solid form or a mixture containing estradiol cypionate?", "kind": "boundary", "id": "conditioned-property-evidence-q03" } ] } ] }, { "id": "storage-and-degradation", "name": "Storage and degradation", "description": "Connects storage history to evidence about preservation or loss of intact ester.", "findings": [ { "id": "stability-supported-disposition", "name": "Stability-supported disposition", "description": "Storage instructions and retest decisions need applicable stability evidence, with ester cleavage treated as a pathway to investigate rather than an assumed explanation for every change.", "questions": [ { "text": "Which stability evidence supports the container, temperature, light and moisture conditions specified for this material?", "kind": "provenance", "id": "stability-supported-disposition-q01" }, { "text": "Do stability-indicating measurements show loss of estradiol cypionate or growth of free estradiol or other degradation products?", "kind": "measurement", "id": "stability-supported-disposition-q02" }, { "text": "After a documented excursion or retest date, what evidence is needed to release, retest or reject the lot?", "kind": "action", "id": "stability-supported-disposition-q03" } ] } ] } ] }, { "id": "handling-and-use-boundaries", "name": "Handling and use boundaries", "description": "Determines which substance-level precautions and restrictions apply while preserving the boundary with formulated medicines.", "rationale": "Estradiol cypionate's relationship to medicinal products makes it especially important to distinguish raw-material evidence from product and patient authorisation.", "layers": [ { "id": "occupational-and-environmental-handling", "name": "Occupational and environmental handling", "description": "Resolves handling requirements for the actual grade, quantity and physical presentation.", "findings": [ { "id": "source-qualified-hazard-controls", "name": "Source-qualified hazard controls", "description": "Hazard classifications, exposure criteria and disposal requirements must be traceable to applicable evidence rather than inferred from therapeutic use.", "questions": [ { "text": "Which current safety data and jurisdictional classifications apply specifically to estradiol cypionate in the supplied material form?", "kind": "provenance", "id": "source-qualified-hazard-controls-q01" }, { "text": "Is an occupational exposure limit or supplier exposure criterion established for this substance, and what authority and units accompany it?", "kind": "measurement", "id": "source-qualified-hazard-controls-q02" }, { "text": "What containment, protective equipment, spill response and waste route are required for the proposed material operation?", "kind": "action", "id": "source-qualified-hazard-controls-q03" } ] } ] }, { "id": "raw-material-to-product-interface", "name": "Raw material to product interface", "description": "Defines what substance evidence can establish when the ester is supplied for formulation or another regulated use.", "findings": [ { "id": "use-specific-eligibility", "name": "Use-specific eligibility", "description": "Material eligibility depends on documented quality and applicable restrictions; sterile-product suitability and clinical use require linked evidence outside this model.", "questions": [ { "text": "Which jurisdiction, intended use and effective date govern the acquisition, transfer or processing of this estradiol cypionate lot?", "kind": "definition", "id": "use-specific-eligibility-q01" }, { "text": "Which requirements belong to the raw substance, and which belong to the formulated medicine, including sterility, excipient composition and administration?", "kind": "boundary", "id": "use-specific-eligibility-q02" }, { "text": "What additional evidence must be obtained before this lot can enter the intended formulation or regulated workflow?", "kind": "action", "id": "use-specific-eligibility-q03" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This is recalled information; no sources were consulted.", "Verify current jurisdiction-specific approvals, pharmacopoeial requirements, and substance hazard classifications.", "Melting point, solubility, purity specifications, and formulation-dependent pharmacokinetics require source verification." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of estradiol cypionate this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "CAS Registry Number", "value_or_pattern": "313-06-4", "note": "Identifies estradiol cypionate as a chemical substance, not a finished injectable formulation." }, { "scheme": "Molecular formula", "value_or_pattern": "C26H36O3", "note": "Describes elemental composition but does not uniquely identify structure or stereochemistry." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of estradiol cypionate this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Active ingredient in depot estrogen injections for menopausal symptoms and estrogen deficiency.", "Used in some feminizing hormone therapy regimens.", "Combined with medroxyprogesterone acetate in some monthly injectable contraceptives." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of estradiol cypionate this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Molar mass", "typical_range": "396.57", "unit": "g/mol" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of estradiol cypionate this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Systemic estrogen exposure can increase thromboembolic risk.", "Unopposed systemic estrogen can increase endometrial hyperplasia and cancer risk in people with a uterus.", "Depot administration produces prolonged exposure that cannot be promptly stopped by discontinuing subsequent doses.", "Injection-site reactions and vehicle-related hypersensitivity concern the finished formulation as well as its active ingredient." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of estradiol cypionate this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Availability, approved indications, and use in combination contraceptives vary by jurisdiction." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of estradiol cypionate this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Estradiol", "difference": "Estradiol has a free 17β-hydroxyl group; estradiol cypionate esterifies that group and releases estradiol through hydrolysis." }, { "name": "Estradiol valerate", "difference": "The 17β ester is pentanoate rather than cyclopentylpropionate, affecting formulation and release characteristics." }, { "name": "Estradiol cypionate injection", "difference": "The injection is a formulated medicinal product with a specified concentration and vehicle; the substance is its active chemical ingredient." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of estradiol cypionate this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which authoritative sources confirm the exact structure, stereochemistry, CAS number, PubChem CID and any applicable EC identifier for this registry entry?", "Which current pharmacopoeial or other recognised specifications apply to estradiol cypionate, and what assay and impurity requirements do they establish?", "What experimentally supported physical-property data are available, including melting behaviour, solvent-specific solubility and whether a boiling-point value is meaningful before decomposition?", "Which degradation pathways, storage conditions and retest periods are supported for the neat substance and relevant material grades?", "Which current GHS classifications, occupational exposure criteria and raw-substance restrictions apply in the intended jurisdictions, and where is authoritative guidance absent?" ], "statistics": { "bundles": 5, "layers": 9, "findings": 15, "questions": 28 } }